PE20030358A1 - Formulacion en combinacion de derivados de propanol amina sustituidos con arilo, junto con otras sustancias activas - Google Patents

Formulacion en combinacion de derivados de propanol amina sustituidos con arilo, junto con otras sustancias activas

Info

Publication number
PE20030358A1
PE20030358A1 PE2002000744A PE2002000744A PE20030358A1 PE 20030358 A1 PE20030358 A1 PE 20030358A1 PE 2002000744 A PE2002000744 A PE 2002000744A PE 2002000744 A PE2002000744 A PE 2002000744A PE 20030358 A1 PE20030358 A1 PE 20030358A1
Authority
PE
Peru
Prior art keywords
aryl
active substances
amine derivatives
alkyl
formulation
Prior art date
Application number
PE2002000744A
Other languages
English (en)
Spanish (es)
Inventor
Heiner Glombik
Wendelin Frick
Hans-Ludwig Schafer
Werner Kramer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10140170A external-priority patent/DE10140170A1/de
Priority claimed from DE2001142455 external-priority patent/DE10142455A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20030358A1 publication Critical patent/PE20030358A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
PE2002000744A 2001-08-22 2002-08-16 Formulacion en combinacion de derivados de propanol amina sustituidos con arilo, junto con otras sustancias activas PE20030358A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10140170A DE10140170A1 (de) 2001-08-22 2001-08-22 Kombinationspräparate von arylsubstituierten Propanolaminderivaten mit weiteren Wirkstoffen und deren Verwendung
DE2001142455 DE10142455A1 (de) 2001-08-31 2001-08-31 Kombinationspräparate von arylsubstituierten Propanolderivaten mit weiteren Wirkstoffen und deren Verwendung

Publications (1)

Publication Number Publication Date
PE20030358A1 true PE20030358A1 (es) 2003-04-23

Family

ID=26009945

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000744A PE20030358A1 (es) 2001-08-22 2002-08-16 Formulacion en combinacion de derivados de propanol amina sustituidos con arilo, junto con otras sustancias activas

Country Status (21)

Country Link
US (1) US20030158094A1 (enExample)
EP (1) EP1420826A2 (enExample)
JP (1) JP2005505538A (enExample)
KR (1) KR20040027963A (enExample)
CN (1) CN1638801A (enExample)
AR (1) AR035284A1 (enExample)
BR (1) BR0211995A (enExample)
CA (1) CA2457974A1 (enExample)
CO (1) CO5560569A2 (enExample)
HR (1) HRP20040172A2 (enExample)
HU (1) HUP0401908A2 (enExample)
IL (1) IL160475A0 (enExample)
MX (1) MXPA04001256A (enExample)
NO (1) NO20040726L (enExample)
NZ (1) NZ531292A (enExample)
PA (1) PA8553101A1 (enExample)
PE (1) PE20030358A1 (enExample)
PL (1) PL366855A1 (enExample)
RU (1) RU2004108120A (enExample)
UY (1) UY27418A1 (enExample)
WO (1) WO2003018059A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023245A (en) * 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
ATE268758T1 (de) * 1997-04-04 2004-06-15 Aventis Pharma Gmbh Hypolipidämische propanolaminderivate
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
DE19845406C2 (de) * 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE69911058T2 (de) * 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen

Also Published As

Publication number Publication date
BR0211995A (pt) 2004-09-28
MXPA04001256A (es) 2004-05-27
RU2004108120A (ru) 2005-04-10
PL366855A1 (en) 2005-02-07
CO5560569A2 (es) 2005-09-30
HRP20040172A2 (en) 2004-10-31
PA8553101A1 (es) 2003-06-30
CA2457974A1 (en) 2003-03-06
NO20040726L (no) 2004-02-19
JP2005505538A (ja) 2005-02-24
HUP0401908A2 (hu) 2005-01-28
EP1420826A2 (de) 2004-05-26
UY27418A1 (es) 2002-11-29
KR20040027963A (ko) 2004-04-01
CN1638801A (zh) 2005-07-13
US20030158094A1 (en) 2003-08-21
IL160475A0 (en) 2004-07-25
AR035284A1 (es) 2004-05-05
WO2003018059A3 (de) 2003-11-13
NZ531292A (en) 2005-08-26
WO2003018059A2 (de) 2003-03-06

Similar Documents

Publication Publication Date Title
UY27357A1 (es) Nuevos agentes antidiabéticos .
AR037247A1 (es) Compuestos inhibidores de dipeptidil peptidasa iv (dp-iv), sus composiciones farmaceuticas y usos, y metodos de tratamiento de enfermedades de humanos tales como tolerancia alterada a la glucosa, diabetes tipo 2 e hiperglucemia
CO5560569A2 (es) Productos de combinacion de derivados de propanolamina arilo sustituidos con otros ingredientes activos y su uso
AR034010A1 (es) Difenilazetidinonas, medicamentos que contienen estos compuestos, procedimiento para su preparacion, y su utilizacion para la preparacion de medicamentos
GT200300268A (es) Nuevos derivados fluoroglucosidos heterociclicos, medicamentos que contienen estos compuestos y el uso de los mismos
PE20030333A1 (es) Compuestos biciclicos aromaticos sustituidos con amino-alquilo, procedimiento para su preparacion y su utilizacion como medicamentos
AR035285A1 (es) Formulaciones en combinacion de derivados de1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilizacion.
PE20030549A1 (es) Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados
GT200100146A (es) Activadores de glucoquinasa acetamida benzenica sustituida con atomos de alfa-acilo y alfa-heteroatomo.
DE60034354D1 (de) Verbindungen zum schutz von hydroxylgruppen und ihre anwendung
AR063786A1 (es) Derivados de 1,4 -benzotiepina-1,1 dioxido sustituidos con radicales bencilo, productos farmaceuticos que comprenden estos compuestos y su uso
AR035631A1 (es) Compuestos quimicos
AR035548A1 (es) Compuestos organicos
NO20022334D0 (no) Ny sammensetning og anvendelse
DE60225331D1 (de) Pharmazeutische zusammensetzungen mit metformin und glibenclamid zur behandlung von diabetes mellitus typ ii
ATE234847T1 (de) Organosiliziumverbindungen mit n-substituierter benzimidazol-benzazolgruppe oder benzofuranyl- benzazolgruppe, diese enthaltende sonnenschutzzusammensetzungen, und deren verwendungen
AR029005A1 (es) FORMULACION LíQUIDA ESTABLE SIN AGUA O CASI SIN AGUA DE BENCIMIDAZOLES SUSTITUIDOS, PROCESO PARA SU PREPARACIoN, USO DE ESTA FORMULACIoN, Y USO DE POLIETILENGLICOL Y UNA SAL DE SODIO O POTASIO DE UN INHIBIDOR DE H+, K+-ATP ASA
PE20040084A1 (es) Combinaciones de medicamentos que contienen compuestos heterociclicos y un nuevo agente anticolinergico
MXPA04009476A (es) Compuestos de (tiazol-4,2-disustituidos-5-il)amina como inhibidores de la pde7.
FI961507A0 (fi) Antrasyklinonijohdannaiset ja niiden käyttö amyloidoosissa
TW200505446A (en) Inhibitor of cox
ATE263166T1 (de) Neue benzoxazole mit pde-hemmender wirkung
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
ATE422531T1 (de) Organische verbindungen
BRPI0415497A (pt) composto processo para a sua preparação , composição farmacêutica que compreende o mesmo, utilização de um composto e método para o tratamento de diabetes do tipo ii

Legal Events

Date Code Title Description
FA Abandonment or withdrawal